# OnCo record paper-durvalumab-endometrial-gynecol-oncol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-durvalumab-endometrial-gynecol-oncol-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-durvalumab-endometrial-gynecol-oncol-2022" ;
  schema:name "Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)"@en ;
  schema:description "Phase 2 or 3 results paper on Durvalumab in Endometrial cancer, in Gynecologic Oncology (2022), one of the most cited Europe PMC records with Durvalumab in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-durvalumab-endometrial-gynecol-oncol-2022/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.ygyno.2022.02.025>, <https://pubmed.ncbi.nlm.nih.gov/35287967/>, <https://europepmc.org/article/MED/35287967> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/j.ygyno.2022.02.025> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Post CCB, Westermann AM, Boere IA, et al." ;
  onco:journals <https://onco.cc/journals/gynecologic-oncology/> .